Citations

Clear

263 citation(s) found for "Mayo, Samantha".

Spinal Cord and Nerve Root Involvement in Histiocytic Neoplasms
Vilaseca, Andreu , Borre, Carla, Go, Ronald S , Abeykoon, Jithma P , Rech, Karen , Banks, Samantha , Flanagan, E P , Goyal, Guarav , Koster, Matthew J , Vassallo, Robert , Tobin, W Oliver

Mayo Clinic

Neurology | October 15, 2026 | Volume: 107 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000218559 | PMID 42879725 Get It

“Railroad Track” Brain Fluorodeoxyglucose-PET Sign in Antiphospholipid Syndrome–Related Posterior Cortical Atrophy
Segal, Yahel , Aksamit, Allen J. , McCarter, Stuart J , Syc-Mazurek, Stephanie B , Chen, John J , Cascino, Gregory D , Banks, Samantha

Mayo Clinic

Neurology | October 7, 2026 | Volume: 107 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000218621 | PMID 42842850 Get It

Comparative Dosing of Bevacizumab for Radiation Necrosis: Impact of Tumor Type on Edema Response
Schultz, Sydney E., Labib, Milisia, Breit, Jeff, Barreto, Jasón, Mead‐Harvey, Carolyn , Behairy, Mohamad, Nurioglu, Aylin, White, Jessica, Valerius, Allison , Taraba, Jodi L. , Soefje, Scott, Hoefs, Gena, Caron, Samantha, Ruff, Deborah, Uhm, Joon, Lachance, Daniel, Kizilbash, Dr Sani, Campian, Jian, Geyer, Susan, Neth, Bryan, Sener, Ugur, Schultz, Sydney , Barreto, Jason N. , Behair, Mohamad, White, Jessica B. , Karbhari, Nishika , Taraba, Jodi L , Soefje, Scott A. , Hoefs, Gena E, Caron, Samantha, Ruff, Michael W. , Uhm, Joon H. , Lachance, Daniel Honore , Kizilbash, Sani H. , Campian, Jian , Geyer, Susan M. , Neth, Bryan J. , Sener, Uğur

Mayo Clinic

No container title available | September 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10795946/v1 Get It

Abstract Purpose Bevacizumab is an effective treatment for radiation necrosis; dose dependent radiographic and edema response data are lacking. Methods Multicenter, retrospective cohort study of adult patients with primary central nervous system tumors or brain metastases who received bevacizumab for radiation necrosis between June 2021 and July 2024. Patients were grouped by bevacizumab dose (7.5 mg/kg vs 10 mg/kg administered every three weeks). Primary outcome was edema response, assessed by a blinded neuro-oncologist. Secondary outcomes included contrast enhancing disease response, clinical response, adverse events, treatment discontinuation, and re-dosing for recurrent radiation necrosis. Analyses were performed with and without adjustment for tumor type. Results 104 patients were included (7.5 mg/kg, n = 53; 10 mg/kg, n = 51). Edema response differed between dosing groups in unadjusted analyses (p = 0.032), favoring the 7.5 mg/kg cohort; however, this association was attenuated after adjustment for tumor type. Contrast enhancing disease response did not differ between groups in either unadjusted or adjusted analyses (p = 0.43). Clinical response was higher in the 7.5 mg/kg group (65.2% vs 37.8%, p = 0.013). Tumor type differed significantly between cohorts (p < 0.001), with more primary CNS tumors in the 10 mg/kg group. Rates of adverse events, treatment discontinuation, and re-dosing were similar. Conclusions While lower-dose bevacizumab was associated with greater edema reduction in unadjusted analyses, this effect was attenuated after accounting for tumor type. Importantly, 7.5 mg/kg dosing appeared sufficient for achieving edema control and contrast enhancing disease response. These findings support an individualized approach to bevacizumab dosing in radiation necrosis and highlight the need for prospective, tumor-stratified studies.
Pearls & Oy-sters: DPPX Antibody-Associated Encephalitis in a Patient With Diarrhea, Tremor, Ocular Flutter, and Cognitive-Psychiatric Changes
Sosa, Santiago Martinez , Webb, Lauren M. , Thomsen, Anna, Rigler, Nicole, Coon, Elizabeth A. , Toledano, Michel , McKeon, Andrew , Banks, Samantha A. , Martinez Sosa, Santiago , Paz Soldán, M Mateo , Coon, Elizabeth Anne , Toledano, Michel , McKeon, Andrew , Syc-Mazurek, Stephanie B , Banks, Samantha , Soldán, M. Mateo Paz , Syc‐Mazurek, Stephanie B.

Mayo Clinic

Neurology | September 1, 2026 | Volume: 107 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000218522 | PMID 42679339 Get It

Provider Perspectives on Community Birth Transfers: Analysis of Personal Values and Attitudes Toward Community Birth Among Maternity Care Providers in Community and Hospital Settings
Shao, Samantha, Unadkat, Krishna, Li, Yan, Geldmaker, Laura, Cho, Courtney McEwen, Lamppa, Julie, Smith, Rebecca , Larish, Alyssa , McEwen Cho, Courtney, Geldmaker, Laura , Lamppa, Julie A.

Mayo Clinic

Journal of Midwifery & Women's Health | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jmwh.70167 | PMID 42576725 Get It

Introduction Out‐of‐hospital community births account for 1.6% to 2% of births in the United States and are associated with fewer obstetric interventions but increased neonatal risk. Little is known about how maternity care providers’ characteristics, values, and prior exposure to community birth influence attitudes toward community birth. Methods We conducted an observational cross‐sectional survey using a 40 to 43 item Research Electronic Data Capture questionnaire distributed October 2 to 30, 2024. Eligible participants (“providers”) included in‐hospital physicians, midwives, community birth providers, and registered nurses. The survey assessed demographics, practice characteristics, provider values, prior community birth experience, and attitudes toward community birth. Descriptive statistics were used to summarize characteristics. Group comparisons between in‐hospital and community birth providers were conducted using analysis of variance and χ 2 or Fisher exact tests. Associations between attitudes and provider values were evaluated using linear models with Bonferroni correction. Results Sixty‐seven providers completed the survey (51 in hospital, 16 community based). Most respondents were female (89.6%) and White (77.6%), with a median of 7 years in practice (IQR, 3‐14.5). Attitudes significantly differed by role ( P = .007) and credentials ( P = .002). In‐hospital providers reported safety concerns about community birth and perceived antenatal counseling to be inadequate. Perceived patient distrust during transfer was common among both in‐hospital and community‐based providers (69% and 81%, respectively). After adjustment for provider role and multiple comparisons, no significant differences in personal values were noted by attitude group; however, providers with positive attitudes toward community birth were more likely to believe that patients value compassion (β = 2.3, P = .004). Discussion Provider attitudes toward community birth appear to be shaped more by professional role and clinical experience than by differences in underlying value systems. High levels of perceived patient distrust during transfer highlight the need for interventions that strengthen compassion across maternity care settings.
Polymeric nanoparticle-mediated siRNA delivery into primary human bronchial airway cells
Thompson, Michael A., Hamrick, Samantha K. , Borkar, Niyati A. , Ravi, Preetham , Çiçek, Yağız Anıl , Lehot, Victor , Goswami, Ritabrita , Nagaraj, Harini , Nasim, Nourina , Rotello, Vincent M , Pabelick, Christina M , Prakash, Y S , Borkar, Niyati , Rotello, Vincent M. , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

American Journal of Physiology-Cell Physiology | August 10, 2026 | Volume: 331 | Issue: 3 | Pages: C783-C796

10.1152/ajpcell.00127.2026 | PMID 42572107 Get It

siRNA delivery to target cellular processes is an appealing area in lung diseases such as asthma. To realize this potential requires efficient, targeted cytosolic delivery without cellular toxicity or siRNA degradation. We demonstrate the efficacy of PONI-Guan nanoparticles in accessing airway epithelial and smooth muscle cells with specific siRNA targeting of mRNAs of interest while maintaining barrier integrity and avoiding cellular toxicity.
SUPC-01 USE OF THE SELECTIVE PLASMA KALLIKREIN INHIBITOR RZ402 FOR STABILIZATION OF CEREBRAL EDEMA RELATED TO METASTATIC MELANOMA – RESULTS OF A SINGLE PATIENT PROTOCOL
Sener, Ugur, Schultz, Sydney, Galloway, Taylor , Brickley, Vince, Mason, Charles, Huebert, Carey, Headlee, Amy, Burns, Terry, Yan, Elizabeth, Neth, Bryan, Caron, Samantha, Hood, Davelyn , Breit, Jeff, Sener, Uğur , Huebert, Carey, Neth, Bryan J. , Caron, Samantha

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.096 Get It

Abstract Background Peritumoral brain edema (PTBE) is a frequent complication of CNS tumors and radiation therapy (RT). PTBE is primarily treated with corticosteroids, but prolonged use is associated with severe toxicities including myopathy and immunosuppression. Bevacizumab, an alternative treatment, is not recommended in patients with thromboembolic events and intracerebral hemorrhage. Plasma kallikrein is a key driver of tumor-related edema. By targeting this pathogenic enzyme, the orally delivered inhibitor, RZ402, may provide therapeutic value by controlling edema and decreasing corticosteroid use. Methods In this single-patient investigational new drug protocol, we report results from use of RZ402 for treatment of cerebral edema related to metastatic melanoma and RT. Results A 74-year-old man with BRAF-wildtype melanoma had a right frontal and basal ganglia hemorrhagic metastasis not amenable to resection, treated with stereotactic RT (30 Gy, 5 fractions), followed by ipilimumab and nivolumab. MRI obtained 5 months after RT showed increased edema associated with midline shift. After 12 weeks of treatment with high-dose dexamethasone (16 mg daily), edema remained persistent and patient was unable to tolerate dose reduction below 4 mg daily. Course was complicated by a pulmonary embolus prompting initiation of anticoagulation, leading to deferral of bevacizumab. Patient was treated with RZ402, which was tolerated well with no reported toxicities. Dexamethasone was discontinued over 4 weeks. Follow up imaging 6 weeks after RZ402 initiation and off dexamethasone demonstrated stability without rebound edema. Patient did experience adrenal insufficiency characterized by severe fatigue, managed with low-dose prednisone. RZ402 was discontinued after 8 weeks of treatment with patient remaining clinically stable. Conclusion Despite persistent edema after prolonged use of corticosteroids, the selective plasma kallikrein inhibitor RZ402 was associated with radiographic stabilization and discontinuation of dexamethasone for this patient. These findings support prospective evaluation of RZ402 in treatment of symptomatic cerebral edema related to CNS tumors.
Dysregulated iron metabolism in remodeling of aging asthmatic human airways
Ngassie, Maunick Lefin Koloko, Ortiz, Yamillie , Ravi, Preetham , Pfeffer-Kleemann, Daniel A., Hamrick, Samantha K. , Thompson, Michael A., Pabelick, Christina M. , Prakash, Y. S. , Ngassie, Maunick Lefin Koloko , Koloko Ngassie, Maunick Lefin , Pfeffer-Kleemann, Daniel , Pabelick, Christina M , Prakash, Y S , Fang, Yun Hua

Mayo Clinic

American Journal of Physiology-Cell Physiology | July 29, 2026 | Volume: 331 | Issue: 3 | Pages: C558-C572

10.1152/ajpcell.00897.2025 | PMID 42526057 Get It

Iron is an essential element for cellular homeostasis and functionality. Increased iron in the lung is associated with aging and asthma in the elderly (AIE). Using human airway smooth muscle cells from young versus elderly versus AIE patients, we found that dysregulated iron metabolism (more than iron accumulation), resulting in activation of antioxidant systems and increased susceptibility to ferroptosis, occurs in AIE, contributing to cell hyperplasia and matrix remodeling of aging and AIE.
Characterization of the circulating T-cell landscape in cutaneous lichen planus patients 2266750
Shao, Samantha, Mangold, Aaron, Silva, Henrique Borges da

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.1105 Get It

Abstract Introduction Cutaneous lichen planus (cLP) is a T cell—mediated skin disease in which cytotoxic CD8+ T cells attack basal keratinocytes at the dermo-epidermal junction. While studies have characterized T cell subsets in lesional tissue, circulating immune signatures in cLP are incompletely defined. We performed deep immunophenotyping of circulating T-cell subsets to map systemic alterations in cLP patients vs healthy controls. Methods We included 12 treatment-refractory cLP patients (mean age 63.6 ± 13.6 years) and 2 healthy controls (37.5 ± 10.6 years). Whole blood was profiled for 27 markers by flow cytometry. Sequential gating: singlets → live → CD3+ T cells → CD4+/CD8+/γδ; FOXP3+ Tregs were defined within CD4+. Frequencies were expressed as % of the immediate parent population. Group comparisons used two-tailed exact Mann—Whitney tests with Hodges—Lehmann median differences. Results Across frozen specimens, cLP patients exhibited broad T-cell activation. Proliferation increased in CD4 (Ki67+, p &lt; 0.05), CD8 (6.785% vs 0.885%; Δ=5.90; p &lt; 0.05), and Tregs (83.0% vs 46.8%; Δ=34.1; p &lt; 0.05). Intracellular CTLA-4 was higher on CD4 (11.07% vs 2.615%; Δ=8.45; p &lt; 0.05), CD8 (21.05% vs 9.30%; Δ=11.6; p &lt; 0.05), and γδ T cells (47.20% vs 24.45%; Δ=22.75; p &lt; 0.05). CXCL13+ cells expanded in CD4 (28.20% vs 12.45%; Δ=15.5; p &lt; 0.05), CD8 (18.05% vs 3.595%; Δ=14.46; p &lt; 0.05), γδ (2.805% vs 0.465%; Δ=2.285; p &lt; 0.05), and Tregs (7.56% vs 1.17%; Δ=6.39; p &lt; 0.05). Tregs were TBET-high (78.75% vs 61.55%; Δ=17.3; p &lt; 0.05); GITR+ Tregs trended up (p = 0.1978). Conclusion cLP blood displays a CXCL13+, proliferative T-cell signature with increased intracellular CTLA-4 across CD4, CD8, γδ, and Treg compartments. CXCL13 elevation aligns with lesion-level literature implicating CXCL13+ CD8+ T cells that are suppressed in JAK-STAT therapy responders. Tregs exhibit a GITR upregulated, Th1-like phenotype that suggests loss of suppressive capacity, warranting further investigation on whether Treg dysfunction plays a causative role in cLP. Funding Source N/A Topic Categories Immune Mechanisms of Human Disease (HUM)
Spinal Cord Involvement in Histiocytic Neoplasms: Insights From a Single-center Cohort Study (P4-6.011)
Vilaseca-Jolonch, Andreu, banks, Samantha, Valinotti, Julio Sartori, GO, RONALD, Abeykoon, Jithma, Young, Jason, Koster, Matthew, Vassallo, Robert, Ryu, Jay, Ravindran, Aishwarya, Bennani, N Nora, Rech, Karen, Tobin, W., Vilaseca-Jolonch, Andreu, Go, Ronald S. , Abeykoon, Jithma P. , Goyal, Gaurav , Vassallo, Robert , Ravindran, Aishwarya , Bennani, N. Nora , Rech, Karen L.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216818 Get It